The biotech licenses a China-developed anti-B7-H3 ADC.
ApexOnco Front Page
Recent articles
Armed with $75m the company takes a risky asset into the clinic.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
But results come from a curated dataset, with no in-trial comparator.
The latest projects newly into human trials include BNT3212.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
Tolerability could decide first-line therapy in EGFRm disease.
